Clinical Trials | March 14, 2026
Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
Glucon-D maintained its leadership position with a 59% MAT market share
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
Winlevi is authorized in EU for the treatment of acne vulgaris
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
Subscribe To Our Newsletter & Stay Updated
